A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

Published:2024-03-06 Issue:1 Volume:16 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Frey Gerhard¹^ORCID,Cugnetti Ana Paula G.¹,Liu Haizhen¹^ORCID,Xing Charles¹^ORCID,Wheeler Christina¹^ORCID,Chang Hwai Wen¹^ORCID,Boyle William J.¹^ORCID,Short Jay M.¹^ORCID

Affiliation:

1. Research & Development, BioAtla Inc, San Diego, CA, USA

Funder

BioAtla Inc

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2024.2322562

Reference27 articles.

1. EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale

2. EpCAM: A New Therapeutic Target for an Old Cancer Antigen

3. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis

4. Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside

5. FDA Approval: Blinatumomab

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

2. Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer;Frontiers in Oncology;2024-04-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP